Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
About this study
This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. The main objectives are to assess treatment response rates, progression-free survival, and treatment safety, and to identify prognostic and predictive biomarkers associated with response to immunotherapy. Biological samples including blood, stool, and body fluids (if available) will be collected at predefined time points and analyzed for molecular tumor markers. Imaging assessments (CT or PET/CT) will be performed before treatment initiation and during follow-up to evaluate response. The study aims to improve identification of patient subgroups who benefit from immunotherapy and those who do not, supporting better personalized treatment strategies.
- Condition
- Metastatic Melanoma, Melanoma
- Tested
- Immunotherapy
- Sponsor
- Institute of Oncology Ljubljana
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Metastatic Melanoma, Melanoma
- Age ≥ 18 years
- Metastatic (diffuse) melanoma
- Planned first-line immunotherapy treatment
- Signed informed consent for participation in the study
Exclusion 3
- Age \< 18 years
- Inability to provide informed consent
- Any condition preventing participation or sample collection according to investigator judgment
Where
1 site, 1 recruiting
Institute of Oncology Ljubljana
Ljubljana, Slovenia
Contact
-
Tanja Mesti, MD
015879287 tmesti@onko-i.si
-
Klavdija Korošec
Potential match only. Final eligibility is determined by the study team.